{"id":"NCT00947752","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Safety of New Formulation of Glatiramer Acetate","officialTitle":"An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2009-09","completion":"2009-11","firstPosted":"2009-07-28","resultsPosted":"2011-06-09","lastUpdate":"2017-03-14"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Remitting Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Glatiramer Acetate","otherNames":["F1"]},{"type":"DRUG","name":"Experimental Glatiramer Acetate","otherNames":["F2"]}],"arms":[{"label":"F1 Glatiramer acetate 20mg/1.0ml","type":"ACTIVE_COMPARATOR"},{"label":"F2 Glatiramer acetate 20mg/0.5ml","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA. In addition, the investigators will evaluate the side effects of the two formulations of GA.","primaryOutcome":{"measure":"Subject-reported Pain Associated Immediately After Each Injection","timeFrame":"5 weeks of injections","effectByArm":[{"arm":"F1 Glatiramer Acetate (GA) 20mg/1.0ml","deltaMin":11.89,"sd":14.325},{"arm":"F2 Glatiramer Acetate 20mg/0.5ml","deltaMin":8.64,"sd":10.825}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://en.wikipedia.org/wiki/Visual_analogue_scale"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":147},"commonTop":[]}}